RIGL
Rigel Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$48.67
+0.35%0
Insider buys (3m)
1
Insider sells (3m)
-$87.5K
Net value (3m)
+62.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | M-Exempt | 1,286 | $24 |
| Sep 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | M-Exempt | 2,000 | $24 |
| Sep 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | M-Exempt | 694 | $13 |
| Sep 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | M-Exempt | 620 | $19 |
| Sep 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | F-InKind | 928 | $48 |
| Sep 3, 2026 | Furey Raymond J. · officer: EVP, GC, CCO & Corp Sec | F-InKind | 877 | $48 |
| Sep 3, 2026 | RODRIGUEZ RAUL R · director, officer: CEO, President | F-InKind | 2,424 | $48 |
| Sep 3, 2026 | Santos David A · officer: EVP, Chief Commercial Officer | F-InKind | 874 | $48 |
| Jul 10, 2026 | HANNAH ALISON L. · officer: EVP, Chief Medical Officer | A-Award | 24,400 | $0.00 |
| Jun 24, 2026 | Ali-Jackson Kamil · director | Sale | 2,500 | $35 |
| Jun 22, 2026 | Santos David A · officer: EVP, Chief Commercial Officer | A-Award | 7,394 | $22 |
| Jun 22, 2026 | Rojkjaer Lisa · officer: EVP, Chief Medical Officer | A-Award | 7,394 | $22 |
| Jun 22, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | A-Award | 7,394 | $22 |
| Jun 22, 2026 | Rojkjaer Lisa · officer: EVP, Chief Medical Officer | A-Award | 9,375 | $15 |
| Jun 22, 2026 | Furey Raymond J. · officer: EVP, GC, CCO & Corp Sec | A-Award | 7,394 | $22 |
| Jun 22, 2026 | RODRIGUEZ RAUL R · director, officer: CEO, President | A-Award | 31,700 | $22 |
| Jun 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | M-Exempt | 2,181 | $13 |
| Jun 3, 2026 | Rojkjaer Lisa · officer: EVP, Chief Medical Officer | F-InKind | 850 | $30 |
| Jun 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | M-Exempt | 1,200 | $19 |
| Jun 3, 2026 | Santos David A · officer: EVP, Chief Commercial Officer | F-InKind | 874 | $30 |
| Jun 3, 2026 | RODRIGUEZ RAUL R · director, officer: CEO, President | F-InKind | 2,424 | $30 |
| Jun 3, 2026 | Furey Raymond J. · officer: EVP, GC, CCO & Corp Sec | F-InKind | 877 | $30 |
| Jun 3, 2026 | Schorno Dean L · officer: EVP & Chief Financial Officer | F-InKind | 928 | $30 |
| May 28, 2026 | Ali-Jackson Kamil · director | Sale | 2,500 | $29 |
| May 19, 2026 | Wasman Jane · director | A-Award | 5,750 | $0.00 |
| May 19, 2026 | MILLER MICHAEL PATRICK · director | A-Award | 5,750 | $0.00 |
| May 19, 2026 | Ali-Jackson Kamil · director | A-Award | 5,750 | $0.00 |
| May 19, 2026 | LAPOINTE ANTHONY GREGG · director | A-Award | 5,750 | $0.00 |
| May 19, 2026 | Frohlich Mark W · director | A-Award | 5,750 | $0.00 |
| May 19, 2026 | HANNAH ALISON L. · director | A-Award | 5,750 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 50Increased 120Reduced 107Sold out 24
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 1,939,818 | Aug 7, 2026 |
| Soleus Capital Management, L.P. | Increased | 1,843,504 | Aug 11, 2026 |
| BLACKROCK, INC. | Increased | 1,768,907 | May 13, 2026 |
| ARMISTICE CAPITAL, LLC | Increased | 1,672,000 | Aug 14, 2026 |
| ARMISTICE CAPITAL, LLC | Increased | 1,280,000 | May 15, 2026 |
| STATE STREET CORP | Increased | 1,120,238 | May 15, 2026 |
| STATE STREET CORP | Reduced | 1,039,994 | Aug 7, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 785,107 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 764,193 | May 15, 2026 |
| AMERICAN CENTURY COMPANIES INC | Increased | 741,718 | Aug 12, 2026 |
| LSV ASSET MANAGEMENT | Increased | 721,666 | Aug 6, 2026 |
| GOLDMAN SACHS GROUP INC | Reduced | 671,878 | Mar 25, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | Increased | 666,426 | May 13, 2026 |
| LSV ASSET MANAGEMENT | Increased | 601,507 | May 11, 2026 |
| MARSHALL WACE, LLP | Reduced | 598,378 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 3, 2026